Company Overview and News
The broad markets saw a massive drop this past week but posted a small recovery to close out the week. This drop off could offer a nice buying opportunity as the third-quarter earnings reporting season gets underway. 24/7 Wall St. has put together a preview of some of the major companies posting their quarterly results this week.
PM NFLX PYPL BAC HON KMI MS KMR CVB HON BAC SLB SYF UAL HON.WI TRI SCL SLB KMRFZ
2018-10-13 seekingalpha - 4
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
GLBS PERY PSX LCII ABT CRM SHPG CSCO MS AMC COF-P SMPL ISRG SYF DVMT IDA JNJ HON.WI MSFT HLUKF LEVL FTCH APHQF UTHR MTW ADS FB SCL NFLX AXP SKX SU BAC COF-D COF-C COF-F AAPL CCI ELAN HUBB CE SU EB SURF TRIP PVTL GSK EOG SIX JPM PATK SBUX CNTTF KMRFZ CNC CNK WMT NKE SHAK AMZN HON KMI TWTR HCSG GSK TRMB EAF KMR AA DXC CVB EBAY REGN SLB BAC DFS CRON STBA SC UAL GOOGL LTXB AHBIF PENN SCL SLB QCOM WFCNP XLNX PM PG PNK CPB PYPL VMW WGO TLRY USB GS MYL JEC SWI XYF WEED DXC.WI ECL ABT IBM CWH WFC HON BUD C TPR CMCSA THO COF BSVN LECO CGC SNY VLTHF V SCHW HP T MRK SNE DPZ
2018-10-08 247wallst - 1
Stocks were looking to open lower on Monday, but it was expected to be a fairly quiet day with the Columbus Day holiday keeping part of the banking system closed. U.S. equity indexes are just under all-time highs, but investors have been seeing lower upside from buying on market pullbacks than in prior years. Now the investing community has to consider how they want to position their investments for the rest of 2018 and into 2019.
HAL FB ABT WMT HUN AAPL CAG TMHC ABT SLB EA GE GEC VOD VOD CBT BHGE KMB PBR MDT BHI BLK VODPF TRI GNE SCL SLB
2018-10-02 reuters - 1
RIO DE JANEIRO, Oct 2 (Reuters) - General Electric Co’s unit Baker Hughes is preparing an offer for a production-sharing deal with Brazil’s Petrobras, a Baker Hughes executive said on Tuesday, as the state-run oil company seeks creative ways to boost output from mature fields.
BHI SLB GEC GE GNE SCL SLB
Investors in Schlumberger Limited (SLB - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 16, 2018 $67.50 Call had some of the highest implied volatility of all equity options today.
SLB 2454 SCL SLB
It has been hard for investors to make some of the same gains in the oil and gas segment since oil prices have recovered handily. That may be about to change, or at least that is the take of Morgan Stanley. The firm issued a series of major upside calls for its clients looking to profit within oil and gas.
WFCNP HAL MS RIG WFC SLB BHGE NBR DO DRQ BHI TRI SCL SLB SGAZF
Chicago, IL –September 13, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Transocean Ltd. (RIG - Free Report) , Chevron Corp. (CVX - Free Report) , Halliburton Company (HAL - Free Report) and Southwestern Energy Company (SWN - Free Report) .
SLB VTNR HBIO ORIG TCP SUMR CVX ICE SCL SLB RIG SGAZF
On the news front, offshore driller Transocean Ltd. (RIG - Free Report) agreed to acquire smaller peer Ocean Rig UDW, Inc. for $2.7 billion, while supermajor Chevron Corp. (CVX - Free Report) scored a big legal victory over pollution claims in Ecuador that protects the company from having to pay $9.5 billion fine.
SLB MPLX LB MPC ORIG COP BHI ETP CVX SCL SLB MMP RIG SGAZF
Shares of Schlumberger Limited (SLB - Free Report) slipped to a 52-week low of $59.25 during the trading session on Sep 7. However, the stock recovered marginally to eventually close at $59.70, which is notably just 0.6% up from the stock’s 3-year low level of $59.32. Shares of the company closed at $59.98 yesterday, up around 0.4% from the closing price as of Sep 7. Let’s have a detailed view on the overall picture of the company to uncover the reason behind the stock’s dismal run on the bourses.
BHI SLB SCL SLB
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to LSE:SCL / SCHLUMBERGER on message board site Silicon Investor.